

Special Issue

Prostate Cancer: from Molecular Imaging to Immunological and Target Therapies II

Message from the Guest Editors

More recently, prostate-specific membrane antigen (PSMA) has emerged as an attractive biomarker both for positron emission tomography (PET) imaging and targeted radionuclide therapy, in the perspective of combining diagnosis and treatment in a unique approach (i.e., “theranostics”). The aforementioned emerging therapeutic options call for an unmet need of imaging/molecular biomarkers, suitable for accurate pre-treatment patient selection and outcome prediction. The aim of this Special Issue is to solicit original research or review articles highlighting the potential usefulness of different molecular probes (18F/11C-choline, 18F-fluciclovine, PSMA-targeting agents, 18F-fluoride, PARP-inhibitors’ analogues) in order to define customized therapeutic pathways in patients affected by PC.

Guest Editors

Dr. Agostino Chiaravalloti

Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy

Prof. Dr. Luca Filippi

Nuclear Medicine Unit, Santa Maria Goretti Hospital, viale Canova snc, 04100 Latina, Italy

Deadline for manuscript submissions

closed (31 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/99159

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).